Prevalence of neutralizing antibodies against liver-tropic adeno-associated virus serotype vectors in 100 healthy Chinese and its potential relation to body constitutions.
Recombinant adeno-associated virus (rAAV) serotype 2, 3 and 8 vectors are the most promising liver-tropic AAV serotype vectors. Liver diseases are significant problems in China. However, to date, few studies on AAV neutralizing antibodies (Nabs) were working with the Chinese population or with the rAAV3 vectors. The present study aimed to determine the prevalence of Nabs in Chinese population against wild-type AAV2, AAV3 and AAV8 capsids as well as additional two AAV3 variants. In addition, we performed a preliminary analysis to investigate the potential influence of traditional Chinese medicine body constitutions on AAV Nabs. Our work demonstrated that the majority of healthy Chinese subjects were positive for AAV Nabs, with the order of AAV2>AAV3=AAVLK03>AAV8. There was no difference between: 1) AAV3 and its variants; 2) male and female subjects; and 3) different age cohorts (≤35, 36-50, and ≥51 years old). People in the Qi-deficiency constitution had significantly increased AAV8 Nabs than people in the Gentleness constitution. Our studies may have impact on the future clinical design of AAV-based gene therapy in the Chinese population.
Division of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida 32611, USA.|Shands Cancer Center, University of Florida College of Medicine, Gainesville, Florida 32611, USA.
Chen
C
Ling
Changhai Hospital of Traditional Chinese Medicine, Second Military Medical University, Shanghai 200433, China.
Yuan
Y
Wang
Department of Traditional Chinese Medicine, 401 Hospital of the Chinese People's Liberation Army, Qingdao 266071, Shandong Province, China.
Ying-lu
YL
Feng
Changhai Hospital of Traditional Chinese Medicine, Second Military Medical University, Shanghai 200433, China.
Ya-ni
YN
Zhang
Changhai Hospital of Traditional Chinese Medicine, Second Military Medical University, Shanghai 200433, China.
Jun
J
Li
Changhai Hospital of Traditional Chinese Medicine, Second Military Medical University, Shanghai 200433, China.|Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Xin-rui
XR
Hu
Changhai Hospital of Traditional Chinese Medicine, Second Military Medical University, Shanghai 200433, China.
Li-na
LN
Wang
Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Mao-feng
MF
Zhong
Changhai Hospital of Traditional Chinese Medicine, Second Military Medical University, Shanghai 200433, China.
Xiao-feng
XF
Zhai
Division of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida 32611, USA.
Irene
I
Zolotukhin
Division of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida 32611, USA.|Shands Cancer Center, University of Florida College of Medicine, Gainesville, Florida 32611, USA.
Arun
A
Srivastava
Changhai Hospital of Traditional Chinese Medicine, Second Military Medical University, Shanghai 200433, China.|E-Institute of TCM Internal Medicine, Shanghai Municipal Education Commission, Shanghai 201203, China.
Chang-quan
CQ
Ling
D000328:Adult; D000368:Aged; D057134:Antibodies, Neutralizing / Q000097:blood*; D000914:Antibodies, Viral / Q000097:blood*; D001824:Body Constitution; D000229:Dependovirus / Q000145:classification / Q000276:immunology*; D005260:Female; D005822:Genetic Vectors; D006801:Humans; D008099:Liver / Q000821:virology*; D008297:Male; D008875:Middle Aged; D065288:Serogroup
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral